The Federal Board of Revenue (FBR) has officially initiated a high-profile money laundering case against a prominent Karachi-based pharmaceutical company and its five directors. This legal action follows a deep-rooted investigation into a massive Rs7.5 billion settlement that was allegedly routed through a non-profit organization to settle personal liabilities.
According to the First Information Report (FIR) registered by the Directorate of Intelligence and Investigation, the controversy stems from a legal feud between the company’s founder and its directors. In December 2023, a settlement was reached requiring the directors to pay Rs7.5 billion in their personal capacity. However, the FBR alleges that instead of using private funds, the directors utilized the accounts of the company they controlled. This payment was then recorded as a business expense under “Other Indirect Expenses” to claim tax deductions for the 2024 Tax Year.
Furthermore, the non-profit educational trust associated with the firm, which manages a well-known university and several schools, was reportedly used as a conduit for these transactions. The Large Taxpayers’ Office in Karachi has already revoked the entity’s non-profit status, citing that donation funds were diverted for the personal benefit of the directors.
The case has drawn significant public attention following social media posts from legal experts who labeled the FBR’s swift action as a “shakedown.” In contrast, the FBR maintains that they followed due process, issuing notices under the Anti-Money Laundering Act and the Income Tax Ordinance. Despite the directors providing responses in April 2026, the authorities deemed their explanations unsatisfactory and lacking evidence.
With bank accounts targeted and arrests sought, this case highlights the government’s aggressive stance on financial crimes and corporate tax evasion. The pharmaceutical industry is now watching closely as the judicial proceedings unfold in the Sindh High Court.
